Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type

NCT02549196 is registered in ClinicalTrials.gov with Chase Pharmaceuticals Corporation, an affiliate of Allergan plc as lead sponsor.

NCT NCT02549196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02549196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
Lead sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Phase
Phase 2
Overall status
Completed
Start date
October 7, 2015
Completion date
September 28, 2017
Enrollment
28 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

dementia of alzheimer's type